These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10882230)

  • 1. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices.
    Manco-Johnson MJ; Nuss R; Jacobson LJ
    J Lab Clin Med; 2000 Jul; 136(1):74-9. PubMed ID: 10882230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assay of factor VIII: C in heparinized plasma: a polybrene neutralization method.
    Cumming AM; Wensley RT; Delamore IW
    Thromb Haemost; 1986 Feb; 55(1):58-60. PubMed ID: 3085265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
    Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T
    Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method.
    Torita S; Suehisa E; Kawasaki T; Toku M; Takeo E; Tomiyama Y; Nishida S; Hidaka Y
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):185-9. PubMed ID: 21245748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII inhibitor assay using skin puncture blood samples.
    Hinchliffe RF; Bellamy GJ; Lilleyman JS
    J Clin Pathol; 1990 May; 43(5):433-4. PubMed ID: 2115051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of factors which affect the measurement of factor VIII inhibitor by Bethesda method].
    Takahashi Y; Arai M; Fukutake K
    Rinsho Byori; 1996 May; 44(5):449-55. PubMed ID: 8676565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
    Kessler CM; Bernstein Z; Ghesani S; Shamsipour Z; Frances C; Zucker ML; LaDuca FM
    Am J Hematol; 1996 Mar; 51(3):181-5. PubMed ID: 8619397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of heparin and protamine from plasma.
    Thompson AR; Counts RB
    J Lab Clin Med; 1976 Dec; 88(6):922-9. PubMed ID: 993645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the neutralization of rabbit antibodies to human factor VIII.
    Kernoff PB; Kaelin AC
    Thromb Haemost; 1977 Oct; 38(3):707-16. PubMed ID: 74103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.
    Verbruggen B; Novakova I; Wessels H; Boezeman J; van den Berg M; Mauser-Bunschoten E
    Thromb Haemost; 1995 Feb; 73(2):247-51. PubMed ID: 7792738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of heparinase to neutralize residual heparin in blood samples drawn through pediatric indwelling central venous catheters.
    Keller FG; DeFazio J; Jencks F; Steiner M; Rogers J; Ritchey AK
    J Pediatr; 1998 Jan; 132(1):165-7. PubMed ID: 9470022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catheter-drawn blood cultures: is withdrawing the heparin lock beneficial?
    Everts R; Harding H
    Pathology; 2004 Apr; 36(2):170-3. PubMed ID: 15203754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation.
    Favaloro EJ; Bonar R; Duncan E; Earl G; Low J; Aboud M; Just S; Sioufi J; Street A; Marsden K;
    Thromb Haemost; 2006 Jul; 96(1):73-8. PubMed ID: 16807654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparity between one- and two-stage factor VIII assays in measuring VIIIC in heparinized plasma.
    Rock G; Palmer DS
    Thromb Haemost; 1985 Dec; 54(4):780-3. PubMed ID: 3937275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparinase: in vivo activity and immunogenicity in rabbits.
    Klein MD; Drongowski RA; Linhardt RJ; Cooney CL; Langer RS
    J Lab Clin Med; 1983 Nov; 102(5):828-37. PubMed ID: 6631173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.